Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2020

View Archived Issues

From African genomes, big insights with small sample size

Commercial antibodies underwhelm for studies of PP2A

TUSC2 as a novel therapeutic target in thyroid carcinoma

Gedeon Richter patents alpha-7 nicotinic receptor positive allosteric modulators

New compounds for RNA virus infections described by CNRS and others

Rodin Therapeutics identifies new HDAC inhibitors

New Trk-A, Trk-B and Trk-C inhibitors discovered at BenevolentAI Bio

Pfizer identifies new monoglyceride lipase inhibitors

FDA clears IND application for BXCL-501 for the treatment of opioid withdrawal symptoms

Lamivudine shows promising safety and activity in p53 mutant mCRC

Phase Ib results for ficlatuzumab plus gemcitabine and nab-paclitaxel in PDAC

Interim phase I/II data for LOAd-703 plus nab-paclitaxel/gemcitabine in PDAC

Reducing stem cell senescence protects against aging

Interim phase I data on Arrowhead's ARO-APOC3 and ARO-ANG3 show improvements in lipid parameters

Phase IIb study of SAR-442168 in relapsing MS meets primary endpoint

Tonix stops enrollment in phase III PTSD study of Tonmya for futility

Antitumor activity seen with pembrolizumab in advanced anal squamous cell carcinoma trial

BiondVax reports preliminary phase II data on M-001 universal influenza vaccine candidate

Arthrosi begins phase IIa study of AR-882 for gout

Atreca and Merck & Co. collaborate to identify antibody targets in oncology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...